Abstract: A compound of Formula (I) wherein Y1, Y2, X1, X2, R1, R2, R3, R4, R5, R6, R8, and R9 are as defined herein; and pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.

Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3, and Z are as defined herein, and methods of making and using the same.

Abstract: An optical sensor includes pixels. Each pixel has a photodetector and a semiconductor guard ring around the photodetector. The photodetector and the semiconductor guard ring are dimensioned so that a fill factor of the pixel is less than or equal to 50%.

Abstract: In an embodiment, a TDC includes: a clock input configured to receive a reference clock that is synchronized with a first event; a clock generation circuit configured to generate a first clock at a first output of the clock generation circuit based on the reference clock, the first clock having a second frequency lower than the reference clock; a data input configured to receive an input stream of pulses, where the input stream of pulses is based on the first event; a sampling circuit having an input register, the sampling circuit coupled to the data input, the sampling circuit configured to continuously sample the input stream of pulses into the input register based on the reference clock; and output terminals configured to stream time stamps based on the input stream of pulses at the second frequency, where the stream of time stamps is synchronized with the first clock.

Abstract: The present invention relates to methods for treating Neisseria Gonorrhoeae infection which comprises administering to a subject in need thereof novel 1,2-dihydro-2a,5,8a-triazaacenaphthylene-3,8-dione compounds: or pharmaceutically acceptable salts thereof and/or corresponding pharmaceutical compositions.

Abstract: The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions and treatment methods or uses as antibacterials for bacterial infections.

Abstract: The invention relates to a method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, the polypeptide sequence comprises a chimeric antigen receptor therefore the present invention is useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled.

Abstract: The present invention relates to a crystalline hydrate of the compound (2S,3R)-isopropyl 2-(((2-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-benzo[d]imidazol-5-yl)methyl)amino)-3-hydroxybutanoate edisylate and to its use in the treatment of various disorders for which a BET inhibitor is indicated, in particular inflammatory and autoimmune diseases, and cancers. Processes for the manufacture of this crystalline form and pharmaceutical compositions comprising the crystalline form are also disclosed and form part of the present invention.

Abstract: Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.

Abstract: The present invention relates to the use in therapy of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof, to pharmaceutically acceptable salts of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione and to pharmaceutical formulations comprising 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof.

Abstract: A solids heat exchanger (10) is in the form of a shell and tube arrangement having a shell section (11) through which heated oil (12) passes and a tube section (13). A screw conveyor (14) extends along its length and has a drive motor (15). Drill cuttings or other hydrocarbon contaminated materials are fed in through an inlet (16) and then conveyed along the tube (13) where heat transfer takes place. On exiting the tube (13) oil and water vapour rises and escapes through a first outlet (17) while the now cleaned drill cuttings or other materials fall through a second outlet (18) forming a discharge zone. The apparatus aims to reduce the oil content of the solids to less than 0.5%. The solids can then simply be disposed of. The base oil can be reclaimed and reused.

Abstract: A ceramic toilet pan 12 has a raised rear portion 18 to which a hinge tube 28 may be accurately located and fixed in position for example by adhesive using a jig 22 despite variations in pan body size due to ceramic firing, a water pump 82 and air pump 102 being provided for flushing the toilet pan 10 when a seat 58 and lid 56 are in a closed position, the seat and lid being rotationally mounted to the pan 12 by a horizontal hinge pin 180 located in the hinge tube 28, a latch member 194 being provided for latching the lid 56 and seat 58 closed, a cistern having an overflow weir 320.

Abstract: A waste disposal apparatus for disposing of waste materials using aerobic decomposition includes a decomposition chamber, a waste inlet configured to admit waste materials into the decomposition chamber, a water feed system configured for supplying feed water to the decomposition chamber and a drain system configured for draining drain liquid from the decomposition chamber. The apparatus also includes a sensing system configured to sense the volume VF of feed water supplied to the decomposition chamber and the volume VD of drain liquid drained from the decomposition chamber, and a computing device that is configured to determine the quantity of waste material processed by the waste disposal apparatus from the sensed volumes VF and VD.

Abstract: Provided are aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.

Abstract: An electronic device includes a carrier substrate having a front face. An electronic chip is mounted on the front face of the carrier substrate and includes an optical component. An encapsulation cover is mounted on top of the front face of the carrier substrate and bounds a chamber within which the chip is situated. A front opening extends through the cover and is situated in front of the optical component. An optical element, designed to allow light to pass, is mounted within the chamber at a position which covers the front opening of the encapsulation cover. The optical element includes a central region designed to deviate the light and having an optical axis aligned with the front opening and the optical component. A positioning pattern is provided on the optical element to assist with mounting the optical element to the cover and mounting the cover to the carrier substrate.

Abstract: The present invention relates to the compound (2R,2?R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1?-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.

Abstract: SPADs detect photons of a return light pulse and output corresponding pulse signals. First and second counters, when enabled in response to phase measurement value, are configured to count the pulse signals. The phase measurement value is set for a subsequent iteration of the return light pulse in response to processing of first and second count values of the first and second counters, respectively, for a current iteration. If the first count value exceeds the second count value by more than a difference threshold limit, the phase measurement value is decremented for the subsequent iteration. Otherwise, the phase measurement value is incremented for the subsequent iteration. If the difference threshold limit is not satisfied, the phase measurement value may be maintained for the subsequent iteration, but one of the counters is preloaded for the subsequent iteration with a value equal to a magnitude of the difference between the count values.

Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.